User:Mr. Ibrahem/Tremelimumab

Tremelimumab, sold under the brand name Imjudo, is a medication used to treat hepatocellular cancer that cannot be removed by surgery alone and certain types of non-small cell lung cancer (NSCLC) which has spread to other parts of the body. It is generally used with durvalumab. It is given by gradual injection into a vein.

Common side effects include rash, diarrhea, tiredness, itchiness, and muscle pain. Other side effects may include immune system problems such as pneumonitis, colitis, and hepatitis; and infusion reactions. Use in pregnancy may harm the baby. It is a monoclonal antibody and immune checkpoint blocker that blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).

Tremelimumab was approved for medical use in the United States in 2022. As of 2022 the manufacturer has applied for approval in Europe. In the United States 75 mg costs about US$10,300 as of 2022.